Christoffer Gebhardt

University Medical Center Hamburg-Eppendorf

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (10)

Ralf Gutzmer

Ruhr-Universität Bochum

Selma Ugurel

Christian Gorzelanny

University Medical Center Hamburg-Eppendorf

Jessica C. Hassel

Heidelberg University

Rebecca Lee

The University of Manchester

UNITED KINGDOM

Markus V Heppt

Universitätsklinikum Erlangen

Julia Huynh

Charité - Universitätsmedizin Berlin

Sebastian Haferkamp

University of Regensburg

Cyrill Géraud

Klaus Pantel

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christoffer Gebhardt

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (10)

Ralf Gutzmer

Selma Ugurel

Christian Gorzelanny

Jessica C. Hassel

Rebecca Lee

Markus V Heppt

Julia Huynh

Sebastian Haferkamp

Cyrill Géraud

Klaus Pantel

Make your next move.

Christoffer Gebhardt

Research Interests

Explore related searches

Contact this professor

Articles (20)

Age matters: Rethinking SLNB's reliability in melanoma mortality prediction.

Erfolgreiche Behandlung eines Checkpoint‐Inhibitor‐assoziierten bullösen Pemphigoids mit Dupilumab bei Angiosarkom: Successful treatment of checkpoint inhibitor‐associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma.

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.

Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma.

Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.

Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma.

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives

Current and Future Clinical Applications of ctDNA in Immuno-Oncology

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma

Immune checkpoint blockade for organ-transplant recipients with cancer: A review

Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG

Meeting Report: 47th Annual Meeting of the “Arbeitsgemeinschaft Dermatologische Forschung”

Collaborators (10)

Ralf Gutzmer

Selma Ugurel

Christian Gorzelanny

Jessica C. Hassel

Rebecca Lee

Markus V Heppt

Julia Huynh

Sebastian Haferkamp

Cyrill Géraud

Klaus Pantel

Make your next move.